Trace-Ability Inc Profile last edited on: 6/7/2018
CAGE: 6YCC3
UEI: S11KA2DGF4J6
Business Identifier: Radio-pharmaceutical quality control 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 33
County: Los Angeles
Congr. District: 33
County: Los Angeles
Public Profile
Traceability Inc. has developed a series of radio-pharmaceutical quality control tests that can be run on a single plate reader in combination with an innovative consumable kit. The company's Tracer-QC system is based on assays that yield optical signals that are measured by the plate reader and compiled into a report on compliance with all relevant QC standards using Trace-Ability's 21 CFR Part 11-compliant software. Through a distribution partnership with LabLogic Systems Inc., the company offers instruments, kits, training, service and support.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $1,299,987 | |
| Project Title: Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based cancer imaging PET tracers on a single platform | ||||
| 2024 | 2 | NIH | $4,008,450 | |
| Project Title: Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers. | ||||
| 2023 | 2 | NIH | $2,458,401 | |
| Project Title: Analytical Methods for Automated Quality Control of Cancer Pet Imaging Tracer - [F-18]FDG | ||||
| 2021 | 1 | NIH | $168,087 | |
| Project Title: Rapid pre-release sterility test for PET Drugs. | ||||
| 2020 | 2 | NIH | $1,732,934 | |
| Project Title: Development of Completely Automated Quality Control Procedures for 4 PET Imaging Tracers That Will Increase Production Throughput and Lead to Expanded Diversity of PET Imaging Available to Patients | ||||
Key People / Management
Arkadij Elizarov -- CEO
Artem Lebedev -- CTO
Artem Lebedev -- CTO
Company News
There are no news available.
